AirNexis Therapeutics

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)Small molecule
Chronic Obstructive Pulmonary Disease

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (4)
June 2027 (1)
HSK39004Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-06-11 · NCT07658339 · CT.gov ↗
What to watch
July 2027 (1)
HSK39004Phase 2Chronic Obstructive Lung Disease (COLD)
Est. primary completion 2027-07 · NCT07425210 · CT.gov ↗
What to watch
September 2027 (1)
HSK39004Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-09-30 · NCT07583849 · CT.gov ↗
What to watch
December 2027 (1)
HSK39004Phase 3COPD (Chronic Obstructive Pulmonary Disease)
Est. primary completion 2027-12-24 · NCT07634367 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultHSK39004Phase 2b HSK39004-T1-202 (NCT07108699) met its primary endpoint
AirNexis Therapeutics · Source ↗

Financial reports

No financial reports recorded.